



Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc. Retains Alliance Advisors, LLC to Implement Investor Relations Program

HOUSTON--Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas announced today it has retained Alliance Advisors, LLC as the Company's investor relations firm. Alliance Advisors will immediately initiate a proactive and targeted investor relations campaign. Alan Sheinwald, President of Alliance Advisors, and his team will be advising the Company in all facets of public financial communications.

The customized investor relations plan will include the proper positioning of Bio-Path's corporate message, development of all investor related materials, such as press releases, corporate profiles and presentation materials, as well as building long-term investor relationships with key members of the professional investment community. Alliance Advisors will also provide the Company with premier information resources to institutional investors, hedge funds, independent portfolio managers, buy-side and sell-side analysts, small to large retail brokerage firms, and accredited individual investors.

"After a thorough process, we have selected Alliance Advisors to serve as our direct link with the investment community. We strongly believe that their industry expertise will aid us in effectively communicating our business strategy and operational goals to the market," said Mr. Peter Nielsen, President and CEO of Bio-Path. Alliance Advisors is well-respected and has an outstanding track record working with key institutional investors."

"Bio-Path's groundbreaking liposomal drug delivery system represents an exciting opportunity within the vast cancer treatment marketplace," stated Alan Sheinwald, President of Alliance Advisors. "We strongly believe that the Company has positioned itself to succeed in this arena due to its experienced management team, strong corporate strategy and significant intellectual property."

About Bio-Path Holdings, Inc.

Bio-Path is developing leading edge, patented, liposomal drug delivery systems with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded (siRNA) and single stranded (antisense) nucleic acid compounds with the potential to revolutionize the treatment of cancer and other

diseases where drugable targets of disease are well characterized. For more information, please contact: www.biopathholdings.com.

About Alliance Advisors, LLC

Alliance Advisors, LLC is a focused and dedicated organization that acts as a premier informational resource for institutional investors, hedge funds, buy and sell-side analysts, small to large brokerage firms and accredited investors. Alliance Advisors helps their clients' companies package their corporate information in a clear, concise and consistent manner while facilitating introductions to the right investor(s) at the most opportune time.

Contact:

Bio-Path Holdings, Inc.

Douglas P. Morris, VP Corporate Development

801-580-2326

Or

Alliance Advisors, LLC.

Thomas Walsh, Vice President

212-398-3487